在医疗现场钆基对比剂取消使用特征:基于FDA启发的药物指南对钆沉积的15个月评估
单中心回顾性队列评估2017年10月至2019年1月间计划接受钆基对比剂(GBCM)但实际未用的MRI检查,期间实施FDA启发的钆沉积患者告知单干预。GBCM取消率为0.22%(131/58,837),研究期间无显著变化;无取消因担心钆沉积,38%因肾功能损害,21%原因不明。FDA启发告知单未显著改变GBCM取消频率。
要点
- GBCM在医疗现场取消率为0.22%(131/58,837;95%CI 0.19-0.26),研究期间无显著变化。
- 无取消(0/131)因患者陈述担心钆沉积。
- 取消原因中肾功能损害占38%(50/131;95%CI 30-47),原因不明占21%(28/131;95%CI 13-30)。
核心结论
- FDA启发的关于钆沉积的患者告知单未显著改变GBCM取消频率,医疗现场GBCM取消仍不常见。
研究设计与样本
- 单中心回顾性队列审查,纳入2017年10月至2019年1月计划接受GBCM但实际未用的MRI检查,研究期间(2017年12月至2018年5月)实施FDA启发的钆沉积患者告知单干预,采用过程控制图统计评估GBCM取消趋势。
诊断标准与关键数值
- GBCM取消率0.22%(131/58,837;95%CI 0.19-0.26),研究期间无显著变化。
- 无取消(0/131)因陈述担心钆沉积。
- 因肾功能损害取消占38%(50/131;95%CI 30-47)。
- 因不明原因取消占21%(28/131;95%CI 13-30)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the effect of United States Food and Drug Administration (FDA)-inspired patient handouts, regarding gadolinium retention, on the frequency of patient-initiated cancellations of gadolinium-based contrast media (GBCM) at the point of care.
METHODS: This is a single center retrospective cohort review of MRI examinations protocolled to receive GBCM but performed without GBCM from October 2017 to January 2019. The study period spans an FDA-inspired safety intervention (December 2017 to May 2018) to provide patients with a handout on gadolinium retention. Examinations were coded according to rationale for GBCM cancellation. Process control charts were created to statistically evaluate trends in GBCM cancellations over time.
RESULTS: From October 2017 to January 2019, GBCM was canceled at the point of care for 0.22% (131/58,837; 95% CI 0.19-0.26) of examinations in which GBCM was indicated. This did not significantly vary during the study period. No cancellations (0/131) were due to stated concern for gadolinium retention. However, 38% (50/131; 95% CI 30-47) were canceled due to kidney impairment and 21% (28/131; 95% CI 13-30) were canceled for an unknown reason.
CONCLUSION: FDA-inspired handouts informing patients about gadolinium retention did not significantly change the frequency of GBCM cancellation. GBCM cancellations at the point of care remain uncommon.
引用
- O'Donohue LS, Shankar PR, Stein EB, et al. Characteristics of gadolinium-based contrast media cancellation at the point of care: a 15-month assessment of FDA-inspired medication guides on gadolinium retention. Abdom Radiol (NY). 2020. PMID: 32812066. doi:10.1007/s00261-020-02670-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。